Back to top
more

Verona Pharma (VRNA)

(Real Time Quote from BATS)

$15.56 USD

15.56
155,992

+0.25 (1.63%)

Updated Apr 26, 2024 01:43 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's What Could Help Verona Pharma PLC American Depositary Share (VRNA) Maintain Its Recent Price Strength

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here's Why Verona Pharma PLC American Depositary Share (VRNA) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Verona Pharma PLC American Depositary Share (VRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts See a 95% Upside in Verona Pharma PLC American Depositary Share (VRNA): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 95.5% upside potential for Verona Pharma PLC American Depositary Share (VRNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Verona Pharma PLC American Depositary Share (VRNA)? Wall Street Analysts Think 110%

by Zacks Equity Research

The mean of analysts' price targets for Verona Pharma PLC American Depositary Share (VRNA) points to a 109.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's Why Momentum in Verona Pharma PLC American Depositary Share (VRNA) Should Keep going

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

All You Need to Know About Verona Pharma PLC American Depositary Share (VRNA) Rating Upgrade to Strong Buy

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Verona Pharma PLC American Depositary Share (VRNA) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Best Momentum Stocks to Buy for July 20th

by Zacks Equity Research

AN, LAD, and VRNA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 20, 2022.

How Much Upside is Left in Verona Pharma PLC American Depositary Share (VRNA)? Wall Street Analysts Think 283%

by Zacks Equity Research

The consensus price target hints at a 283.3% upside potential for Verona Pharma PLC American Depositary Share (VRNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Best Momentum Stocks to Buy for July 14th

by Zacks Equity Research

LW, VRNA and JBI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14, 2022.

New Strong Buy Stocks for July 14th

by Zacks Equity Research

CHMG, CQP, VRNA, JBI and SYY have been added to the Zacks Rank #1 (Strong Buy) List on July 14, 2022.

Company News for Jun 11, 2021

by Zacks Equity Research

Companies in the news are: SIG, XIN, VRNA, PFE

Verona (VRNA) Initiates Pivotal COPD Studies on Ensifentrine

by Zacks Equity Research

Verona Pharma (VRNA) is developing twice-daily nebulized formulation of ensifentrine as potential maintenance treatment for COPD.

Has Verona Pharma PLC American Depositary Share (VRNA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (VRNA) Outperforming Other Medical Stocks This Year?

Top Ranked Momentum Stocks to Buy for August 6th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 6th.

Top Ranked Momentum Stocks to Buy for August 4th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 4th.

Top Ranked Momentum Stocks to Buy for July 31st

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 31st.

Top Ranked Momentum Stocks to Buy for July 29th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 29th.

Top Ranked Momentum Stocks to Buy for July 28th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 28th

Will Verona Pharma Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor of Verona Pharma

Will Verona Pharma Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Verona Pharma

Abeona Treats First Patient in Pivotal Gene Therapy Study

by Zacks Equity Research

Abeona (ABEO) treats first patient in a pivotal study evaluating its gene-corrected cell therapy, EB-101, as a treatment for recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder.

Verona Pharma Works Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Verona Pharma plc (VRNA) has been struggling lately, but the selling pressure may be coming to an end soon.

Verona Pharma Enters Oversold Territory

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Verona Pharma Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Verona Pharma has been struggling lately, but the selling pressure may be coming to an end soon.